The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst
: Thanks very much, and good morning. David, I wanted to start with -- you made some comments around your observations in the first 100 days.
What are some of the things that you think you can really bring to CVS as the new CEO? And anything else that you'd want to share from an investor
perspective, David, as you think of the first 100 days?
And then if I can also just maybe better understand the guidance, which is better than I had anticipated, the guidance being a good starting point.
Tom made the comment of an opportunity for outperformance. Last year, you gave a better-than number. This year, your range is $5.75 to $6.00.
Can you maybe just talk about the confidence in that number and the potential outperformance around the guidance for 2025? Thanks very much.
Question: Justin Lake - Wolfe Research - Analyst
: Thanks, good morning, I want to follow up on some of your comments there, Tom. First, on your Medicare Advantage trend. Maybe you can give
us a little bit more detail there in terms of what did the trend look like coming out of the year for 2024? And specifically, what are you assuming
for trend in 2025? I know you said it's kind of you're assuming it to keep that pace.
So what the '24 trend and the '25 assumption? And maybe any detail you could share with us on kind of the costs you've taken out of the business
just via the bids, for instance, and how you're seeing your membership mix kind of play out for 2025?
Question: Stephen Baxter - Wells Fargo Securities, LLC - Analyst
: Yeah, hi, thank you. I was hoping you could update us on where the Medicare Advantage margins ended the full year 2024 and what's assumed
in the guidance for 2025. Basically, the pacing of this obviously is going to be a huge area of focus for the investment community. Any kind of
general comments you can talk about progression of MA recovery over the next couple of years beyond 2025 would also be appreciated. Thank
you.
Question: Andrew Mok - Barclays - Analyst
: Hi, good morning. We spent a lot of time talking about Medicare margins, but you also took aggressive actions on the individual ACA business. So
I was hoping you could elaborate on those actions, including any changes to provider networks and expected impact on margins embedded in
guidance? Thanks.
Question: Erin Wright - Morgan Stanley - Analyst
: Great, thanks for taking my question. How should we think about the quarterly progression for MLR? And you gave us some of the detail on your
overall assumptions from a utilization perspective for 2025, but any nuances particularly as we model out for the year, for instance, how IRA should
flow through throughout the year? And any surprises on that front or elements to think about as we think about that quarterly? Thanks.
Question: Ann Hynes - Mizuho Securities USA - Analyst
: Great, thank you. Can you remind us with CostVantage, what is the headwind to growth the first year of the implementation? And when would
you expect that to turn positive for you? And also, I know CostVantage is only focused on commercial contracts right now. Do you eventually
believe it will impact Medicare contracts? And if so, what's the timing on that? Thanks.
Question: Elizabeth Anderson - Evercore ISI - Analyst
: Hi guys, good morning. Thanks so much for the question. Based on the color on the 2025 outlook in particular, I know you said you were looking
at 4 points of Medicaid improvement year-over-year in terms of the pricing. Can you -- and you said that you had 40% of it was sort of caught up.
Can you talk about how that catches up over the course of 2025? Should we think of that as like broadly ratable or are there any other kind of
considerations to think about for that?
|
